SOURCE: Biophan Technologies, Inc.

February 25, 2008 07:11 ET

Biophan to Present at the Sachs Associates 7th Annual North America Forum for Investing & Partnering in Biotech

PITTSFORD, NY--(Marketwire - February 25, 2008) - Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced that chief executive officer, John Lanzafame, will be presenting at the Sachs Associates 7th Annual North America Forum for Investing & Partnering in Biotech to be held at the Fairmont Copley Plaza in Boston, MA on February 25th and 26th. Mr. Lanzafame's presentation is scheduled for today, Monday, February 25, 2008, at 10:30 a.m. ET.

This premier investment and partnering event brings together leaders of the North American and European Biotech Communities. The event has proved over many years an excellent platform for European companies to find North American Partners and for North American investors to meet a broad base of emerging companies.

For more information please visit: http://www.sachsforum.com/boston08/index.html.

About Sachs Associates:

Sachs Associates is a London-based company, which organizes and produces securities and emerging markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated to the highest quality standards in conferencing and, as a result, produces only a limited number of events each year. Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, and are held in major financial centers such as London, New York and Zurich. Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

About Biophan Technologies, Inc.

Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company is helping to commercialize the Myotech Circulatory Support System, which has significant potential to improve the treatment of acute heart failure. Biophan Technologies, Inc. holds a 68% interest in Myotech with rights to acquire additional equity, and is leading Myotech's business development efforts. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expect, or believe may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact Information

  • Contacts:
    Carolyn Hotchkiss
    Biophan Technologies, Inc.
    Communications Manager
    (585) 267-4800
    Email Contact